|
|
 |
Dr. Wang received his MD and PhD degrees from the University of Virginia School of Medicine in Charlottesville, Virginia. He completed his Internal Medicine residency at the Hospital of the University of Pennsylvania. He was a fellow of Medical Oncology at the Fred Hutchison Cancer Center and University of Washington in Seattle where he was a recipient of the ASCO Young Investigator Award. His research was also supported by the Susan G. Komen Foundation and the Avon Foundation. He has authored a number of papers in Science, Immunity, Proceedings of the National Academy of Sciences, Journal of Immunology and Cancer Research. He has a strong interest in targeted treatment for cancers. Dr. Wang is board certified in both Medical Oncology and Internal Medicine. |
 |
| Medical School |
University of Virginia School of Medicine, 1999 |
| Residency Training |
Hospital of University of Pennsylvania, 2001 |
| Fellowship |
Fred Hutchinson Cancer Research Center/University of Washington, 2005 |
| Board Certification |
Internal Medicine, 2003
Medical Oncology, 2004
|
| Awards |
American Society of Clinical Oncology Young Investigator Award, 2005
Avon Foundation Immunotherapy Fellow, 2002-2005
Susan G. Komen Foundation Postdoctoral Fellow, 2005 |
| Hospital Affiliation |
California Pacific Medical Center
University of California San Francisco
Saint Francis Memorial Hospital
|
| Hospital Appointment |
Medical Director
Cancer Genetic Risk Assessment Program
California Pacific Medical Center
|
| Selected Publications |
Wang W, Meadows LR, den Haan JM et al. Human H-Y: the human male specific histocompatibility antigen derived from the SMCY protein. Science 269:1588-90, 1995.
Meadows L, Wang W, den Haan JM et al. The HLA-A*0201-restricted H-Y antigen contains a post-translationally modified cysteine that significantly affects T cell recognition. Immunity 6:273-81, 1997.
den Haan JM, Meadows LM, Wang W et al. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science 279:1054-7, 1998.
Groh V, Li YQ, Cioca D, Hunder NN, Wang W et al. Efficient cross-priming of melanoma, ovarian and breast tumor antigen-specific T cells by dendritic cells sensitized with anti-MICA opsonized tumor cells. Proc Natl Acad Sci USA 102:6461-6, 2005.
Wang W, Epler J, Salazar L and Riddell SR. NY-BR-1 is presented by breast cancer cells and recognized by CD8+ cytotoxic T cells. Cancer Reseach 66:6826-6833, 2006
|
|
|
